O'Reilly; Terence

Patent Applications and Registrations

Patent applications and USPTO patent grants for O'Reilly; Terence.The latest application filed is for "treatment of solid tumors with rapamycin derivatives".

Company Profile

0.13.29

O'Reilly; Terence - Basel N/A CH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Treatment of solid tumors with rapamycin derivatives Grant 8,877,771 - Lane , et al. November 4, 2	2014-11-04
Treatment of solid tumors with rapamycin derivatives Grant 8,778,962 - Lane , et al. July 15, 2	2014-07-15
Treatment Of Solid Tumors With Rapamycin Derivatives App 20140105895 - Lane; Heidi ; et al.	2014-04-17
Treatment Of Solid Tumors With Rapamycin Derivatives App 20130296359 - Lane; Heidi ; et al.	2013-11-07
Treatment Of Solid Tumors With Rapamycin Derivatives App 20130287769 - Lane; Heidi ; et al.	2013-10-31
Treatment Of Solid Tumors With Rapamycin Derivatives App 20130253000 - Lane; Heidi ; et al.	2013-09-26
Treatment Of Solid Tumors With Rapamycin Derivatives App 20130244951 - Lane; Heidi ; et al.	2013-09-19
Treatment of solid tumors with rapamycin derivatives Grant 8,436,010 - Lane , et al. May 7, 2	2013-05-07
Cancer treatment Grant 8,410,131 - Lane , et al. April 2, 2	2013-04-02
Treatment Of Solid Tumors With Rapamycin Derivatives App 20130059877 - Lane; Heidi ; et al.	2013-03-07
Combination comprising N--4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent. App 20120283206 - Bruns; Christian ; et al.	2012-11-08
Treatment Of Solid Tumors With Rapamycin Derivatives App 20120283285 - Lane; Heidi ; et al.	2012-11-08
Treatment Of Solid Tumors With Rapamycin Derivatives App 20120214774 - Lane; Heidi ; et al.	2012-08-23
Cancer treatment with epothilones Grant 7,875,601 - O'Reilly , et al. January 25, 2	2011-01-25
p53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent Grant 7,749,698 - Beuvink , et al. July 6, 2	2010-07-06
Combination comprising a signal transduction inhibitor and an epothilone derivative Grant 7,723,339 - Brandt , et al. May 25, 2	2010-05-25
Combination Comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-p- Yridyl)-2pyrimidine-amine And A Chemotherapeutic Agent App 20090202541 - Bruns; Christian ; et al.	2009-08-13
Combination of Mtor Inhibitor and Antipolate Compound App 20090012105 - Lane; Heidi ; et al.	2009-01-08
Biomarkers For Sensitivity Of Proliferative Diseases To Mtor Inhibitors App 20080214596 - Boulay; Anne ; et al.	2008-09-04
Use Of Bisphosphonates For Pain Treatment App 20080207565 - Fox; Alyson ; et al.	2008-08-28
P53 Wild-Type as Biomarker for the Treatment with Mtor Inhibitors in Combination With a Cytotoxic Agent App 20080194613 - Beuvink; Iwan ; et al.	2008-08-14
Biomarkers for sensitivity of proliferative diseases to mtor inhibitors App 20070167478 - Boulay; Anne ; et al.	2007-07-19
Cancer treatment with epothilones App 20060223867 - O'Reilly; Terence ; et al.	2006-10-05
Cancer treatment with epothilones Grant 7,091,226 - O'Reilly , et al. August 15, 2	2006-08-15
Cancer treatment with epothilones App 20050165071 - O'Reilly, Terence ; et al.	2005-07-28
Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-- 2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent App 20040167134 - Bruns, Christian ; et al.	2004-08-26
Cancer treatment App 20040147541 - Lane, Heidi ; et al.	2004-07-29
Combination comprising a signal transduction inhibitor and an epothilone derivative App 20040132754 - Brandt, Ralf ; et al.	2004-07-08
Use of bisphosphonates for pain treatment App 20040063670 - Fox, Alyson ; et al.	2004-04-01
Cancer treatment with epothilones App 20040024033 - O'Reilly, Terence ; et al.	2004-02-05
Cancer treatment with epothilones Grant 6,635,666 - O'Reilly , et al. October 21, 2	2003-10-21
Cancer treatment with epothilones App 20020028839 - O'Reilly, Terence ; et al.	2002-03-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.